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 Geierman 1 
Background 
 
Every year approximately 3,500 new cases of pediatric Acute Lymphoblastic Leukemia 
(ALL) are diagnosed.1 ALL is characterized by an accumulation of immature B or T 
lymphocytes, known as blasts, in the bone marrow and blood. ALL originates in the bone 
marrow where hematopoietic stem cells differentiate into either myeloid or lymphoid stem cells. 
Lymphoid stem cells further convert into immature cells called lymphoblasts, and the 
lymphoblasts typically further differentiate into mature B or T lymphocytes. Because of the 
proliferation of immature white blood cells in ALL, normal healthy white blood cells can 
become crowded out, leading to a variety of possible symptoms. A child with ALL may display 
signs and symptoms such as bone or joint pain, fever, frequent infections, loss of appetite, 
fatigue, easy bruising, shortness of breath, swollen lymph nodes (painless lumps in the neck, 
underarm, groin, or abdomen), and petechiae (small, flat dark spots due to bleeding under the 
skin).    
Approximately 25% of all cancers diagnosed before age 15 are ALL, and ALL comprises 
19% of cancers among all patients under age 20.2 These statistics make ALL the most common 
pediatric cancer and most frequent cancer-induced cause of death among patients under the age 
of 20.3 Despite these grim facts, successful treatment of ALL has undergone remarkable progress 
within the last 50-60 years. In 1964, survival rates for children with ALL hovered around 10%.4 
Improvements in survival outcomes have continued in the decades since. Analyses from 1975-
1979 indicated a 5-year survival rate for childhood and adolescent ALL patients of 56.8%. 
Subsequent analyses showed 5-year survival rates of 74.9% from 1985-1989 and 83.8% from 
1995-1999.5 Between 1990-1994 1,194 ALL patients died, while 882 died between 1995 and 
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1999, and 687 died between 2000 and 2005. In the period from 2000-2005, 5-year survival rates 
rose to 90.4%, representing a towering achievement in medical progress and collaboration within 
just five decades.6 Improved risk stratification, personalized chemotherapy, and further post-
induction failure treatments promise to further enhance the survival rates of patients.  
 
Incidence 
 
 According to Ward et al. males are diagnosed at a higher rate than females (38.4 for 
males and 30.2 for females where all rates are given per 1,000,000). ALL is more commonly 
diagnosed in highly industrialized nations, where there is a spike in ALL incidence rates between 
ages 2-4. However, the spike is much more pronounced in non-Hispanic white and Hispanic 
children than black children (about 110 for Hispanics, 105 for whites, and 40 for blacks). 
Hispanics are diagnosed at the highest rates altogether, followed by non-Hispanic whites, Asians 
and Pacific Islanders, and non-Hispanic blacks (rates are 44.9, 34.2, 28.7, and 18.3, 
respectively). Though less black children are diagnosed with ALL, disparities in survival rates 
have long been documented. From 1980-1984 the 5-year survival rate disparity between whites 
and blacks was a 21% difference (68% survival for whites, 47% for blacks). However, this 
disparity has decreased sharply over the last few decades to a 6% difference in survival from 
2003-2009 (90% for white, 84% for blacks).7 This disparity may have to do with blacks having 
elevated incidence rates of T-cell based ALL, which is considered a high-risk feature relative to 
B-cell precursor ALL. One favorable prognostic indicator of ALL is hyperdiploidy, which is 
found in low frequencies in black Americans.8 A study by Hunger et al. of the Children’s 
Oncology Group (COG) reported that during the period from 2000-2005, 44.5% of blacks had 
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NCI (National Cancer Institute) high-risk classification group features while just 32.9% of non-
Hispanic whites had NCI high-risk classification features. Hispanics were at a 1.5x higher risk of 
death than non-Hispanics during the period studied.6 This is likely a result of much higher 
incidences of particular genomic aberrations in leukemic cells among Hispanics enrolled in COG 
ALL trials.9 The reason for higher rates of total incidence in Hispanic populations is currently 
unknown. Recent studies have examined genetic susceptibility, increasing trends in obesity 
among Hispanics, and disproportionate exposure to household chemicals.10  
 
Risk Stratification   
 
ALL is a model disease for the utilization of risk-based therapy, and the risk of treatment 
failure determines stratification of treatment intensity. There are several key identifying features 
of ALL that affect classification and prognosis. Patients with less debilitating features are treated 
with less toxic regimens, and conversely, those with profiles of higher-risk disease receive more 
aggressive treatment regimens.11 In relatively recent years, a renewed emphasis has been placed 
on identifying the features that routinely affect prognosis. In 1993, the NCI sponsored a 
workshop in order to define the criteria for risk-based stratification treatment. Workshop 
participants included physicians and scientists from the COG, Pediatric Oncology Group, Dana-
Farber Cancer Institute, and St. Jude Children’s Research Hospital. Based on ALL clinical trials 
and data outcomes of different groups, the NCI group concluded that B-cell precursor patients 
(which make up the vast majority of ALL patients) between ages 1-10 with a presenting white 
blood cell (WBC) count at diagnosis of less than 50,000 cells/microliter would comprise the 
standard-risk category.12 All other patients are classified into the high-risk ALL group (namely 
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those less than 1 year of age, older than 10 years of age, or with an initial WBC greater than 
50,000 cells/microliter). Additionally, patients taking corticosteroids prior to their diagnostic 
blood workup are automatically considered high-risk due to the confounding effects of steroids 
on WBC count.11 
Different conclusions have resulted from different treatment strategies for T-cell ALL, 
and consequently, some institutions automatically label these patients as high risk while other 
institutions continue to rely on classification by age and WBC count for T-cell patients. Hunger 
et al. found that among 21,626 children and adolescents from 1990-2005, patients with T-cell 
ALL had a higher risk of death than patients with B-cell ALL. Additionally, patients classified as 
NCI high risk ALL individuals had a 2.4-3.6 fold increased risk of death when compared with 
NCI standard risk patients.6 Overall, there is consensus that by improving the uniformity of risk 
stratification based therapy, the efficiency of forthcoming ALL research will also improve.  
 
Genetics  
 
Conventionally, the NCI risk stratification features of patient age and WBC count at 
diagnosis have shown the most consistent predictive power. However, numerous other clinical 
and biologic factors have been scrutinized for prognostic value, though few remain after 
multivariate analysis.13 Leukemic cell chromosomal number has been one of the factors to 
routinely appear prognostic, with some research suggesting that the presence of additional 
specific chromosomes may be more noteworthy than a general increase in total ploidy. There are 
also several genetic abnormalities that are associated with better or worse outcomes. However, 
there is generally no consensus on how to incorporate many of the more specific and novel 
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genetic component findings of the disease into high or standard-risk stratification groups, and 
this is due in part to the relatively recent advent of genome-wide analysis of patients which is 
necessary to find these potentially prognostic genetic profiles.14 This lack of consensus can be 
further attributed to inconsistent findings among clinical trial groups when modifying treatment 
plans for a specific genetic abnormality. Distinct genetic irregularities are identified in 
approximately 75-80% of pediatric ALL cases with typical chromosomal and molecular genetic 
analyses, but through the use of genome-wide analysis, genetic abnormalities are found in 
virtually all cases.14 Beyond specific mutations in genes that regulate different hematopoietic 
aspects, two well-documented genetic anomalies associated with better or worse outcomes are 
hypodiploidy and hyperdiploidy. Hyperdiploidy has been associated with favorable outcomes, 
while hypodiploidy is strongly associated with poor outcomes.  
 
 Hyperdiploidy  
 
In about 20-25% of B-cell precursor ALL, patients present with high hyperdiploidy 
(defined as 51 to 65 chromosomes per leukemic cell or a DNA index of greater than 1.16).11 
DNA index is a prognostic factor used specifically in childhood ALL which measures the 
chromosomal material of cancerous cells.15 In 2005, Sutcliffe et al. published a paper in which 
two independent groups, the Children’s Cancer Group (CCG) and the Pediatric Oncology Group 
(POG), examined the significance of three specific trisomies (a type of chromosomal 
abnormality in which there are three copies of a particular chromosome instead of the usual two). 
The two groups both analyzed populations of patients with NCI standard and high-risk 
stratification classifications. A total of 5,484 patients were analyzed (1,582 by the CCG and 
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3,902 by the POG), and eight-year event free survival rates (EFS) of 91% (CCG) and 89% 
(POG) were reported in patients assigned to the standard risk classification groups whose 
leukemic cells had concurrent trisomies of chromosomes 4, 10, and 17. Further analysis from the 
POG showed that hyperdiploidy in general was less of a significant favorable prognostic factor 
without the three crucial trisomies, and this finding supports the conclusions of previous POG 
and CCG studies in which results indicated that specific trisomies hold more favorable 
prognostic weight than general chromosome number for predicting outcome in the same patient 
type (pediatric B-precursor ALL patients).16 For the NCI high-risk classification patients from 
the sample population, no prognostic significance was found regarding the number of agreeable 
trisomies.17  
 
Hypodiploidy 
 
Hypodiploidy (defined as having a modal leukemic cell chromosomal number below 46 
or a DNA index of less than 0.81) has been found to be strongly associated with poor outcomes 
in pediatric ALL patients. Nachman et al. analyzed data on 139 hypodiploid patient cases 
gathered from 10 different cooperative groups and institutions. Patients were grouped based on 
chromosomal number of leukemic cells and 4 categories resulted: 24-29 chromosomes (n=46), 
33-39 chromosomes (n=13), 40-43 chromosomes (n=13), and 44 chromosomes (n=54). Again, 
eight-year EFS rates were analyzed and determined to be just 38.5% ± 4.4% overall. No 
substantial differences were found in outcomes for patients from the 24-29, 33-39, or 40-43 
chromosome groups, but the 44 chromosome group independently had eight-year EFS rates of 
52.2% compared to 30.1% for the remaining three groups collectively. Patients in the 44 
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chromosome group had worse EFS rates if they had a monosomy 7, dicentric chromosome (an 
abnormality in which a chromosome has two centromeres), or both.18 Though hypodiploid 
patients with 45 chromosomes in their leukemic cells were not analyzed in the previously 
discussed study, they have been shown to have significantly better outcomes than those 
hypodiploid patients with less than 45 chromosomes in their leukemic cells.19  
 
Treatment 
 
 Response to initial treatment therapy is also considered to be an especially reliable and 
independent prognostic indicator. Remission induction is the goal of the first of three major 
components of treatment in recently diagnosed ALL patients (some publications consider there 
to be four major components, and all four aspects will be discussed). Complete remission (the 
goal of induction) is usually defined to mean that less than 5% of immature blast cells remain in 
a patient’s bone marrow, and the vast majority of patients achieve this initial milestone.  
 
 Induction 
 
According to pediatric hematology oncology physicians Stacy Cooper and Patrick 
Brown, induction therapy typically lasts 4-6 weeks and consists of chemotherapy with the drugs 
vincristine, anthracycline (doxorubicin or daunorubicin), asparaginase, and corticosteroids 
(prednisone or dexamethasone). Patients are typically admitted to the hospital before beginning 
treatment, but barring any complications, patients may be discharged and continue treatment as 
outpatients. Severe infections are more likely during this phase of treatment.11 Additionally, 
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relapse has been shown to occur universally without additional treatment, necessitating the 
subsequent two phases.20 
 
 Consolidation 
 
In those that successfully achieve remission, the next treatment phase is known as 
consolidation and aims to further reduce the presence of leukemic cells throughout the body. 
This phase lasts about 6-9 months but is dependent upon risk classification of the patient and 
which specific cancer group’s protocol is being followed. Consolidation generally occurs in an 
outpatient setting. Those patients with higher-risk classifications would typically receive longer 
and stronger drug regimens. Some of the primary chemotherapeutic drugs used are 
mercaptopurine, thioguanine, methotrexate, cyclophosphamide, etoposide, and cytarbine. These 
drugs differ from those of the induction phase and are used in certain combinations to improve 
collective effectiveness and reduce drug resistance. Higher risk patients may receive a second 
burst of intense chemotherapy within the consolidation phase known as delayed intensification.11 
 
Maintenance 
 
If the patient remains in remission after both the induction and consolidation phases, then 
the final and longest phase of treatment can commence, known as maintenance. Maintenance is 
significantly longer and less intense than the prior two phases and has been demonstrated to 
reduce the risk of relapse after remission has been achieved.11 However, the precise explanations 
for why maintenance is a necessary phase and the most effective composition of maintenance 
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have yet to be fully elucidated.20 Furthermore, due to the extensive length (2-3 years) and daily 
requirements of the phase, there are issues with patient adherence. Approximately 20% of 
patients are less than 90% adherent, and unfortunately adherence of less than 90% is associated 
with a relapse risk four times higher than patients who are over 90% adherent.21 Maintenance 
treatment is based primarily around antimetabolite therapy with the drugs methotrexate (weekly, 
oral) and mercaptopurine or thioguanine (daily, oral).11 Individual metabolic differences are 
becoming increasingly notable in how they affect the use of these drugs during maintenance.  
 
Intrathecal Therapy 
 
 As previously mentioned, some publications consider there to be a fourth phase of 
standard treatment which involves therapy directed specifically against the central nervous 
system (CNS). Three different methods can be utilized to expunge signs of disease from the 
CNS, and these include cranial irradiation, systemic chemotherapy capable of penetrating the 
blood-brain barrier, and direct intrathecal chemotherapy administration. Most treatment groups 
begin using intrathecal chemotherapy upon induction of remission. Other groups use protocols 
using intrathecal therapy throughout the treatment process while others do not utilize it during 
the maintenance phase.11 During the 1960s and 1970s, cranial irradiation drastically increased 
cure rates in ALL patients. However, it was associated with some increased risk of secondary 
CNS tumors and neurocognitive effects, particularly with younger patients.22 For these reasons 
the use of cranial irradiation has been progressively declining, and it is generally reserved for 
those patients with the highest risk of CNS relapse. Multiple research groups have implemented 
treatment protocols eliminating CNS irradiation entirely for almost all newly diagnosed patients 
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and have seen results similar to those reported by research groups who continue to use irradiation 
treatment. The use of cranial irradiation remains controversial, but currently all research groups 
treat approximately 80% of pediatric patients without CNS irradiation.23   
 
Treatment Failure 
 
Induction failure and relapse are the primary avenues by which treatment may fail. 
Relapse is more common and has experienced little progress in treatment strategies in contrast 
with the increasingly improving outcomes of newly diagnosed ALL patients.24 Though induction 
failure is rarer, it portends more unfavorable outcomes. 
 
Induction Failure 
 
Cooper and Brown report that failure to reach remission after initial induction therapy 
occurs in 3-5% of pediatric ALL patients and forebodes a particularly dismal prognosis – 
approximately 33% overall survival (OS) rates, making induction failure one of the most 
unfavorable possible outcomes during pediatric ALL treatment.11 About 95% of patients do 
reach this important prognostic benchmark of initial complete remission, but for those who do 
not, risk stratification promptly changes. Due to the rarity of induction failure, those who do not 
achieve remission are almost always reclassified into a third risk subgroup, very-high-risk. A 
study by Schrappe et al. examined data from 14 different study groups on 44,017 patients 
between the ages of 0-18 who were recently diagnosed with ALL and had begun treatment. 
1,041 of the total patients experienced induction failure. The study defined induction failure as 
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leukemic blast persistence in the bone marrow, blood, or any extramedullary location between 28 
and 43 days after beginning treatment. Various treatment strategies were employed for induction 
failure patients among the study groups analyzed. Treatments utilized included additional 
chemotherapy, clinical trial enrollment, and hematopoietic stem cell transplantation (HSCT). The 
primary conclusion upon statistical analysis of outcomes and patient data is that there is 
tremendous clinical and biologic heterogeneity among patients who experience induction 
failure.25  
 
Relapsed Disease 
 
Of those who successfully complete induction therapy and advance to further treatment 
phases, approximately 15-20% of ALL patients experience relapsed disease, and cure rates are 
significantly lower following relapse.26 Relapse is the most common cause of treatment failure, 
and like newly diagnosed patients, relapsed ALL patients are risk stratified. Stratification now 
depends primarily upon the length of the first remission and the location of relapse within the 
body (marrow relapses are the most common). Cooper and Brown report that late relapses 
occurring greater than three years after diagnosis have the best prognosis, while relapses between 
18-36 months are given an intermediate prognosis, and those within 18 months of diagnosis have 
the worst outcomes.11 HSCT is used in greater than 50% of relapsed patients, but there are 
multiple different treatment strategies, again depending on which treatment group’s care the 
patient is under.27 There has been a greater influx in recent years of research investigating the 
biology of relapse, antibody-based therapies, and other immunological approaches.24  
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New Treatments and the Optimistic Future of ALL 
 
Blinatumomab and chimeric antigen receptor (CAR) T cell therapy are two new 
innovative immunotherapies that have demonstrated success in treating patients with relapsed or 
refractory ALL. Refractory patients are typically defined as those patients that have relapsed and 
had a second round of additional therapy fail as well. Advances in genomic technology and 
personalized medicine also show promise in the future treatment of ALL. 
 
Blinatumomab 
 
 Blinatumomab (a monoclonal antibody) is a bispecific T-cell engager (BiTE) that exerts 
its effect by facilitating interaction between a patient’s own T and B cells. Blinatumomab 
contains binding sites for two distinct targets: the CD19 antigen on B cells and the CD3 site on T 
cells. By linking both of these cell types, blinatumomab facilitates the activation and production 
of cytotoxic effects by T cells. The drug binds to both benign and malignant cells of B-lineage 
origin. Lysis of CD19-positive cells is directed by the proliferation of T cells and release of 
inflammatory cytokines and cytolytic proteins.28,29 
 In 2016, von Stackelberg et al. published the results of a Phase I/Phase II clinical trial of 
blinatumomab in pediatric patients who had relapsed or refractory ALL. The study was the first 
of its kind in pediatrics and evaluated the safety, pharmacokinetics, recommended dosage, and 
potential for efficacy of the drug. 49 patients (all under the age of 18) were treated in phase I and 
a recommended dosage was determined. 44 patients were treated in phase II, and a total of 70 
received the recommended dosage. 27 patients achieved complete remission (CR) within the first 
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two cycles of drug administration. However, at the end of a 2-year follow-up, of the 27 who 
achieved CR 4 were still in remission. Two had relapsed but were alive, three had withdrawn 
consent, three died in CR after receiving HSCT, and fifteen had relapsed and died. Further 
investigation of blinatumomab is supported based upon the anti-leukemic activity of the drug.30 
 
CAR-T Cell Therapy   
 
On August 30th, 2017, tisagenlecleucel (CD19 directed CAR-T cell therapy) was 
approved by the FDA for certain pediatric and young adult cancer patients, making it the first 
gene therapy available in the United States. This therapy works by genetically modifying a 
patient’s own T-cells so that they can locate and destroy cancerous B cells. The T cells are 
removed from the patient, mailed to a manufacturing center, and genetically altered so that they 
are able to display a specific receptor (a chimeric antigen receptor, or CAR). The cells are then 
infused back into the patient. The CAR receptors on the modified T cells direct them to bind to 
and kill B cells displaying the CD19 antigen.31 A phase I/II study of CAR-T cell therapy 
conducted by the Children’s Hospital of Philadelphia and the University of Pennsylvania showed 
a CR rate of 90% among 30 children with relapsed or refractory ALL.32 In 2018, a second 
comprehensive study of tisagenlecleucel was conducted. The phase II clinical trial was a global, 
25 center collaborative study conducted in relapsed or refractory ALL patients between the ages 
of 3 and 21. 75 patients received treatment, and the overall remission rate was 81% while 45 
patients attained complete remission. The rates of OS and EFS were 90% and 73% respectively 
at 6 months and 76% and 50% at 12 months. There are substantial, though primarily transient, 
risks associated with the therapy, namely cytokine release syndrome (CKS).33 High fever can 
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result from CKS, and in some situations can progress to respiratory and cardiovascular 
compromise. However, there has been success in treating CKS with the drugs etanercept and 
tocilizumab.34 Overall, the use of tisagenlecleucel resulted in high remission rates, and though 
side effects can be severe, they can be mitigated in most patients.  
 
Genome-wide Analysis 
  
Partly in response to the tremendous heterogeneity of patients who experience treatment 
failure, whether it be through relapse or induction failure, there has been a significant amount of 
ALL research focusing on the identification of genetic alterations and the development of new 
classification subtypes. Recent research with genome-wide analysis has also identified clinically 
relevant and novel genetic abnormalities that could serve as treatment targets. These advances in 
biomedical technology are a promising sign of the legitimacy of personalized treatment plans 
maximizing drug effectiveness and minimizing toxicity based individually on distinct genetic 
profiles.35   
Acute Lymphoblastic Leukemia has become a representative success story of the 
triumphs of modern medicine. Before 1960, for the vast majority of patients a diagnosis of ALL 
was essentially a death sentence. Survival rates hovered around an abysmal 10%, and thousands 
of children died every year from the disease. Today, overall survival rates for newly diagnosed 
patients are approximately 90%. This sharp contrast can be attributed to the relentless pursuit of 
research on treatments and the different profiles in which the disease manifests. The 
development of chemotherapeutic agents and the elucidation of the optimal administration of 
these agents have presumably afforded many thousands of children the opportunity to live out 
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their lives. Unfortunately, many patients still die from ALL and its complications, but continued 
research, innovation, and advances in immunotherapy, genomics, and personalized medicine 
provide legitimate reason for optimism about the future outlook of ALL patients who have 
experienced treatment failure. It is not unforeseeable that a day could soon arise when using high 
throughput genomic sequencing, chemotherapy, immunotherapy, and personalized treatment 
plans that all patients could have a legitimate chance of cure. 
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